Key Takeaways The S&P 500 slipped 0.8% on Tuesday, May 6, 2025, falling for a second straight day as investors awaited news ...

Shares of Vertex Pharmaceuticals Inc. VRTX plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

For Vertex, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its newly launched ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that ...

U.S. equities dropped at midday as the markets awaited any news on tariffs and tomorrow's Federal Reserve decision.

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Vertex Pharmaceuticals (VRTX) and Neurocrine Biosciences (NBIX) shares are moving sharply after their respective earnings ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...